In this year's report, we delve into the biotech mindset again, with a special focus on the pain points of the earlier stage, Finding a Partner, from their perspective.
The Biotech Perspective 2023
Finding a Partner, from their perspective
Industry Perspectives
The environmental impact of a top pharma partner and the perception of a partner as
‘green’ is increasingly a consideration for out-licensors.
Early-stage pain points
In the period before an event, out-licensors encounter pain points that impact their
partnering efforts.
Partner and pharma ratings
Over 100 respondents rank their experience in partnering with top pharma companies to
produce an overall ranking by partnering experience.
External innovation continues to be the strategy of choice
External innovation continues to be the strategy of choice for the development and commercialization of therapies in the life sciences.
In 2023, out-licensors still struggle to get their foot in the door while in-licensors struggle to navigate through the noise and find the most suitable asset for their research requirements.
Delving into the biotech mindset
The survey got over 100 responses submitted by biotechs from Europe, North America, and
the Asia-Pacific region which considered for this report.
Survey participants were
recruited via a variety of means including email outreach to participants in the
previous survey, in-person networking at life science events, inserts in newsletters
sent by Inpart media subsidiary Labiotech, and advertising on Life Science Nation.